Premium
Quality of life and resource utilization‐Swedish data from the Care of Late‐Stage Parkinsonism (CLaSP) study
Author(s) -
Norlin Jenny,
Hjalte Frida,
Kruse Christopher,
Dodel Richard,
Rosqvist Kristina,
Odin Per
Publication year - 2022
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/ane.13611
Subject(s) - quality of life (healthcare) , health care , medicine , parkinsonism , scale (ratio) , health economics , parkinson's disease , total cost , rating scale , disease , physical therapy , gerontology , psychology , public health , nursing , business , geography , economics , developmental psychology , cartography , accounting , economic growth
Background Few studies have investigated the health‐related quality of life (HRQoL), resource use and costs in patients with late‐stage Parkinson's disease (PD), and data from the Swedish setting are scarce. Objectives First, we analyse the HRQoL in late‐stage PD in Sweden. Second, we analyse the resource use and costs per severity level. Third, we analyse the relationship between costs and physician‐ and patient reported‐outcome measures. Materials and methods The study was based on Swedish data from the Care of Late‐Stage Parkinsonism (CLaSP) study. The costs of healthcare contacts, drugs, formal and informal care, and productivity loss were collected over three months. Assessments at baseline were used for outcomes (EQ‐5D, Hoehn and Yahr (H&Y), Schwab and England Scale, Unified Parkinson's Disease Rating Scale subscales (UPDRS) and Non‐Motor Symptoms Scale (NMSS)). Costs were estimated in € 2016. Results In total, 106 patients were included. The mean EQ‐5D score in the total group was 0.24 (±0.33). The mean total cost excluding informal care per patient in the three‐month period was approximately €14,097 (BCa 95% CI €12,007 and €16,039). Professional care accounted for the largest share (75 percent) of the total costs. The EQ‐5D, H&Y, Schwab and England Scale, and NMSS were statistically significant predicting factors for total costs. Conclusion Patients with late‐stage PD are a vulnerable patient group that is costly to society and the impairment in patients’ HRQoL is immense. Thus, healthcare decision‐makers should optimize the organization and provision of healthcare for these patients.